Brimonidine Tartrate label

Brimonidine Tartrate

Brimonidine Tartrate Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The lOP lowering efficacy of brimonidine tartrate ophthalmic solution 0.2% diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.

History

There is currently no drug history available for this drug.

Other Information

Brimonidine Tartrate Ophthalmic Solution 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. In solution, brimonidine tartrate ophthalmic solution 0.2% has a clear, greenish-yellow color. It has an osmolality of 280-330 mOsml/kg and a pH of 5.6-6.6 The structural formula is:

Structure Image

C11H10BrN5 • C4H6O6

Mol. Wt. 442.24 (as the tartrate salt)

Chemical Name: 5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate.

CAS Number 59803-98-4

Each mL Contains:

ACTIVE: Brimonidine tartrate: 0.2% (2 mg/mL).

INACTIVES: Citric Acid, Polyvinyl Alcohol, Sodium Chloride, Sodium Citrate, Purified Water. Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH.

PRESERVATIVE ADDED: Benzalkonium Chloride (0.05 mg).

Brimonidine Tartrate Manufacturers

  • Stat Rx Usa Llc
    Brimonidine Tartrate | Stat Rx Usa Llc
    No Recall

    Brimonidine Tartrate | Stat Rx Usa Llc

    Brimonidine Tartrate | Stat Rx Usa Llc

    The recommended dose is one drop of brimonidine tartrate ophthalmic solution 0.2% in the affected eye(s) three times daily, approximately 8 hours apart.

    Brimonidine tartrate ophthalmic solution 0.2% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.